AZD5363 HAS CLINICAL ACTIVITY IN PATIENTS WITH AKT1-MUTANT SOLID TUMORS

被引：3
|
作者：
Hyman, D. M.
Smyth, L. M.
Donoghue, M. T. A.
Westin, S. N.
Bedard, P. L.
Dean, E. J.
机构：
来源：
CANCER DISCOVERY | 2017年 / 7卷 / 07期
关键词：
D O I：
10.1158/2159-8290.CD-RW2017-093
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：662 / 662
页数：1
相关论文
共 50 条
  • [1] Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors.
    Elvin, Paul
    Palmer, Amy
    Womack, Chris
    Tall, Matthew
    Swales, Karen E.
    Garrett, Michelle D.
    Banerji, Udai
    Tamura, Kenji
    Cheung, S. Y. Amy
    Lawrence, Peter
    Lindemann, Justin
    Ambrose, Helen
    Stephens, Christine
    Davies, Barry
    Foxley, Andrew
    Pass, Martin
    Harrington, Elizabeth A.
    Barrett, J. Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363
    Weller, Michael
    Roth, Patrick
    Sahm, Felix
    Burghardt, Isabel
    Schuknecht, Bernhard
    Rushing, Elisabeth J.
    Regli, Luca
    Lindemann, Justin P.
    von Deimling, Andreas
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (03):
  • [3] AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer
    Smyth, Lillian M.
    Oliveira, Mafalda
    Ciruelos, Eva
    Tamura, Kenji
    El-Khoueiry, Anthony
    Mita, Alain
    You, Benoit
    Renouf, Daniel J.
    Sablin, Marie-Paule
    Lluch, Ana
    Mayer, Ingrid A.
    Bando, Hideaki
    Yamashita, Hiroko
    Ambrose, Helen
    de Bruin, Elza
    Carr, T. Hedley
    Corcoran, Claire
    Foxley, Andrew
    Lindemann, Justin P. O.
    Maudsley, Rhiannon
    Pass, Martin
    Rutkowski, Andrzej
    Schiavon, Gaia
    Banerji, Udai
    Scaltriti, Maurizio
    Taylor, Barry S.
    Chandarlapaty, Sarat
    Baselga, Jose
    Hyman, David M.
    CANCER RESEARCH, 2018, 78 (04)
  • [4] Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
    Kenji Tamura
    Jun Hashimoto
    Yuko Tanabe
    Makoto Kodaira
    Kan Yonemori
    Takashi Seto
    Fumihiko Hirai
    Shuji Arita
    Gouji Toyokawa
    Lan Chen
    Hiroshi Yamamoto
    Toshio Kawata
    Justin Lindemann
    Taito Esaki
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 787 - 795
  • [5] Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors
    Tamura, Kenji
    Hashimoto, Jun
    Tanabe, Yuko
    Kodaira, Makoto
    Yonemori, Kan
    Seto, Takashi
    Hirai, Fumihiko
    Arita, Shuji
    Toyokawa, Gouji
    Chen, Lan
    Yamamoto, Hiroshi
    Kawata, Toshio
    Lindemann, Justin
    Esaki, Taito
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 787 - 795
  • [6] Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
    Davies, Barry R.
    Greenwood, Hannah
    Dudley, Phillippa
    Crafter, Claire
    Yu, De-Hua
    Zhang, Jingchuan
    Li, Jing
    Gao, Beirong
    Ji, Qunsheng
    Maynard, Juliana
    Ricketts, Sally-Ann
    Cross, Darren
    Cosulich, Sabina
    Chresta, Christine C.
    Page, Ken
    Yates, James
    Lane, Clare
    Watson, Rebecca
    Luke, Richard
    Ogilvie, Donald
    Pass, Martin
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (04) : 873 - 887
  • [7] Preclinical activity of the AKT inhibitor AZD5363 in PTEN-deficient mouse models of prostate cancer
    De Velasco, Marco A.
    Hatanaka, Yuji
    Kura, Yurie
    Fukushima, Emiko
    Ando, Naomi
    Davies, Barry R.
    Yamamoto, Yutaka
    Oki, Takashi
    Shimizu, Nobutaka
    Yoshimura, Kazuhiro
    Nozawa, Masahiro
    Yoshikawa, Kazuhiro
    Nishio, Kazuto
    Uemura, Hirotsugu
    CANCER RESEARCH, 2015, 75
  • [8] Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors.
    Banerji, Udai
    Ranson, Malcolm
    Schellens, Jan H. M.
    Esaki, Taito
    Dean, Emma
    Zivi, Andrea
    van der Noll, Ruud
    Stockman, Paul K.
    Marotti, Marcelo
    Garrett, Michelle D.
    Davies, Barry R.
    Elvin, Paul
    Hastie, Andrew
    Lawrence, Peter
    Cheung, S. Y. Amy
    Stephens, Christine
    Tamura, Kenji
    CANCER RESEARCH, 2013, 73 (08)
  • [9] A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK
    Emma Dean
    Udai Banerji
    Jan H. M. Schellens
    Matthew G. Krebs
    Begona Jimenez
    Emilie van Brummelen
    Chris Bailey
    Ed Casson
    Diana Cripps
    Marie Cullberg
    Stephen Evans
    Andrew Foxley
    Justin Lindemann
    Paul Rugman
    Nigel Taylor
    Guy Turner
    James Yates
    Peter Lawrence
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 873 - 883
  • [10] A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK
    Dean, Emma
    Banerji, Udai
    Schellens, Jan H. M.
    Krebs, Matthew G.
    Jimenez, Begona
    van Brummelen, Emilie
    Bailey, Chris
    Casson, Ed
    Cripps, Diana
    Cullberg, Marie
    Evans, Stephen
    Foxley, Andrew
    Lindemann, Justin
    Rugman, Paul
    Taylor, Nigel
    Turner, Guy
    Yates, James
    Lawrence, Peter
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 873 - 883
12345